Modulation of the gut microbiome and resistome by antibiotic use, but not by subsequent 2'-fucosyllactose intake, in adults with overweight or obesity.

Lars M M Vliex, Iúri F Godinho Mimoso, Giang N Le, Ellen E Blaak, John Penders

Abstract readRandomized Controlled Trial

In one paragraph

Trial report in Gut microbes, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Lars M M VliexDepartment of Human Biology, NUTRIM Institute of Nutrition and Translational Research in Metabolism, Maastricht University Medical Center+, Maastricht, The Netherlands.

Iúri F Godinho MimosoDepartment of Medical Microbiology, Infectious Diseases and Infection Prevention, NUTRIM Institute of Nutrition and Translational Research in Metabolism, Maastricht University Medical Center+, Maastricht, The Netherlands.ORCID 0009-0003-9994-6081

Giang N LeDepartment of Medical Microbiology, Infectious Diseases and Infection Prevention, NUTRIM Institute of Nutrition and Translational Research in Metabolism, Maastricht University Medical Center+, Maastricht, The Netherlands.ORCID 0000-0001-6660-557X

Ellen E BlaakDepartment of Human Biology, NUTRIM Institute of Nutrition and Translational Research in Metabolism, Maastricht University Medical Center+, Maastricht, The Netherlands.ORCID 0000-0002-2496-3464

John PendersDepartment of Medical Microbiology, Infectious Diseases and Infection Prevention, NUTRIM Institute of Nutrition and Translational Research in Metabolism, Maastricht University Medical Center+, Maastricht, The Netherlands.ORCID 0000-0001-9146-5919

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Antibiotics are widely used to treat bacterial infections, yet overuse and misuse causes disruption of the gut microbiome and spread of antibiotic-resistant bacteria. Presence of antibiotic resistance genes (ARGs) could be a determinant of the response to antibiotics. Supplementation with prebiotics may limit the detrimental antibiotic-induced effects on the microbiome, but whether this results in changes in the gut resistome is unclear. This study investigated the impact of eight-week 2'-fucosyllactose (2'-FL) supplementation after seven-day vancomycin use in 18 adults with overweight/obesity, a subset from a double-blind placebo-controlled randomized intervention. Whole-metagenome shotgun sequencing was used to characterize the gut microbiome and resistome at baseline, after vancomycin use and after supplementation. Seven-day vancomycin use disrupted microbial richness and diversity (

Indexed as

Anti-Bacterial AgentsBacteriaGastrointestinal MicrobiomeObesityOverweightTrisaccharidesVancomycinAdultDouble-Blind MethodDrug Resistance, BacterialFecesFemaleHumansMaleMiddle AgedPrebiotics2'-fucosyllactoseAnti-Bacterial AgentsPrebioticsTrisaccharidesVancomycinantibioticsbody weightGut microbiomeprebioticsresistome

Identifiers

PMID42878177

DOI10.1080/19490976.2026.2746814

PMCPMC13679327

What OpenQuestion holds

Textmetadata

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.